Hoth Therapeutics (NASDAQ:HOTH) Stock Rating Upgraded by Wall Street Zen

Hoth Therapeutics (NASDAQ:HOTH) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $5.00 target price on shares of Hoth Therapeutics in a research report on Monday, August 18th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $4.00.

Hoth Therapeutics Price Performance

Shares of HOTH opened at $1.60 on Friday. The firm has a market capitalization of $21.22 million, a PE ratio of -1.50 and a beta of 0.67. The company’s 50-day moving average is $1.32 and its 200-day moving average is $1.11. Hoth Therapeutics has a fifty-two week low of $0.65 and a fifty-two week high of $3.80.

Hoth Therapeutics (NASDAQ:HOTH) last announced its earnings results on Tuesday, August 12th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.10. Analysts predict that Hoth Therapeutics will post -1.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Hoth Therapeutics

An institutional investor recently raised its position in Hoth Therapeutics stock. Geode Capital Management LLC lifted its stake in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) by 8.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 122,575 shares of the company’s stock after purchasing an additional 9,071 shares during the quarter. Geode Capital Management LLC owned 0.93% of Hoth Therapeutics worth $143,000 as of its most recent filing with the Securities and Exchange Commission. 7.08% of the stock is currently owned by institutional investors and hedge funds.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.